Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial
Authors' conclusion
In this randomized placebo-controlled study of calcitriol administration in kidney transplant recipients on corticosteroid-sparing immunosuppression, calcitriol did not improve bone quality and strength but was associated with higher rates of hypercalcemia.
Study context
- Population
- Kidney transplant recipients aged ≥18 yr on corticosteroid-sparing immunosuppressive regimen; mostly male and Caucasian27 and 27 completed
- Participants
- 67 recipients
- Comparison
- Daily calcitriol 0.5 μg vs placebo for 12 mo after kidney transplantation
- Calcitrioln = 32
- Placebon = 29reference
- Primary endpoint
- % change in cortical density at the radius and tibia vs placebo, measured by HR-pQCT
- Follow-up
- 12 mo
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Areal BMD, volumetric BMD, microarchitecture, bone strength, serum bone markers · 12 mo posttransplantation
- No between-group differences in areal BMD, volumetric BMD, microarchitecture or bone strength, or serum levels of bone markers
- Intent to treat
Further findings
Bone markers in participants with vs without bone loss · 12 mo
- Participants with vs without bone loss had a blunted anabolic response measured by serum bone markers
Safety
| Outcome | P value |
|---|---|
| HypercalcemiaHigher with Calcitriol | P < 0.001 |
Arterial calcification scores
- No changes in arterial calcification scores were observed
Original publication
Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial. J Bone Miner Res. Published 16 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →